Back

Prognostic value of mitral regurgitation in patients with asymmetric hypertrophic cardiomyopathy

11 December 2020 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Live Abstract Presentations - Bad prognosticators: fibrosis and more Imaging of Myocardial Disease EACVI Premium Access EACVI - Best of Imaging 2020

About the speaker

Photo
Associate Professor Milorad Tesic

University Clinical Center of Serbia, Belgrade (Serbia)

6 More presentations in this session

Presentation thumbnail
Predicting heart failure transition and progression: a weighted risk score from bio-humoral, cardiopulmonary and echocardiographic stress testing
Doctor N. Pugliese (Pisa, IT)
Abstract Slides Video
Presentation thumbnail
Long-term evolution of echocardiography parameters in Brugada syndrome patients
Doctor E. Scheirlynck (Lugano, CH)
Abstract Slides Video
Presentation thumbnail
Identification and prognostication of the substrate of ventricular arrhythmia with cardiac magnetic resonance (CMR) imaging in patients with normal echocardiography
Miss S. Younus (Multan, PK)
Abstract Slides Video
Presentation thumbnail
Clinical implications of the morphological features of left ventricular intracavitary thrombi after anterior ST elevation myocardial infarction
Mr P. Vilardell (Girona, ES)
Abstract Slides Video
Presentation thumbnail
Assessment of the CHA2DS2-VASc score in predicting ischemic stroke and death in patients with acute myocardial infarction without atrial fibrillation.
Doctor A. Marques (Almada, PT)
Abstract Slides Video

Access the full session

Session thumbnail
Live Abstract Presentations - Bad prognosticators: fibrosis and more

The Event

Event poster

EACVI - Best of Imaging 2020

11 December - 12 December 2020
You may be interested in
thumbnail
Congress Presentation
What is the best imaging method to assess myocardial viability? 
thumbnail
Congress Presentation
Toxic for the whole heart: from inflammation to radiation
thumbnail
Congress Presentation
Imaging inflammation in acute and chronic pericarditis and response to therapy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources